Haploinsufficiency of the Maspin tumor suppressor gene leads to hyperplastic lesions in prostate

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5143-5151

  Shao, Long Jiang ^a   Shi, Heidi Y ^b   Ayala, Gustavo ^a   Rowley, David ^a   Zhang, Ming ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MASPIN; P21 ACTIVATED KINASE; PROTEIN P27; SERINE PROTEINASE INHIBITOR; SERPIN B5; SERPIN-B5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CELL ADHESION; CELL POLARITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE LOSS; HETEROZYGOSITY; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NEWBORN PERIOD; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; RECOMBINANT GENE; SMOOTH MUSCLE FIBER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL CYCLE; CELL STRAIN 3T3; CONGENITAL MALFORMATION; EMBRYO (ANATOMY); EPITHELIUM CELL; GENETICS; HETEROZYGOSITY LOSS; METABOLISM; ORGANOGENESIS; PHYSIOLOGY; PRENATAL DEVELOPMENT; PROSTATE; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; CELL CYCLE; CELL PROLIFERATION; EMBRYO, MAMMALIAN; EPITHELIAL CELLS; FEMALE; GENES, TUMOR SUPPRESSOR; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; NIH 3T3 CELLS; ORGANOGENESIS; PROSTATE; PROSTATIC HYPERPLASIA; SERPINS; TUMOR CELLS, CULTURED;

EID: 48549086260     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0163     Document Type: Article

References (50)

1. Pemberton PA, Tipton AR, Pavloff N, et al. Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J Histochem Cytochem 1997;45:1697-706.
2. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 1996;93:11669-74.
3. Shi HY, Zhang W, Liang R, et al. Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 2001;61:6945-51.
4. Cher ML, Biliran HR, Jr., Bhagat S, et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A 2003;100:7847-52.
5. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-9.
6. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 2007;446:690-4.
7. Abraham S, Zhang W, Greenberg N, Zhang M. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol 2003;169:1157-61.
8. Ngamkitidechakul C, Warejcka DJ, Burke JM, O'Brien WJ, Twining SS. Sufficiency of the reactive site loop of maspin for Induction of cell-matrix adhesion and inhibition of cell invasion: conversion of ovalbumin to a maspin-like molecule. J Biol Chem 2003;278:31796-806.
9. Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R, Hendrix MJ. Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 1998;58:5681-5.
10. McGowen R, Biliran H, Jr., Sager R, Sheng S. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 2000;60:4771-8.
11. Biliran H, Jr., Sheng S. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 2001;61:8676-82.
12. Pemberton PA, Wong DT, Gibson HL, et al. The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin. J Biol Chem 1995;270:15832-7.
13. Yin S, Lockett J, Meng Y, et al. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 2006;66:4173-81.
14. Al-Ayyoubi M, Schwartz BS, Gettins PG. Maspin binds to urokinase-type and tissue-type plasminogen activator through exosite-exosite interactions. J Biol Chem 2007;282:19502-9.
15. Yin S, Li X, Meng Y, et al. Tumor suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem 2005;280:34985-96.
16. Bailey CM, Khalkhali-Ellis Z, Kondo S, et al. Maspin binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem 2005;280:34210-7.
17. Khalkhali-Ellis Z, Hendrix MJ. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res 2007;67:3535-9.
18. Machtens S, Serth J, Bokemeyer C, et al. Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer 2001;95:337-42.
19. Zou Z, Zhang W, Young D, et al. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin Cancer Res 2002;8:1172-7.
20. Chen Z, Fan Z, McNeal JE, et al. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 2003;169:1316-9.
21. Affara NI, Coussens LM. IKKα at the crossroads of inflammation and metastasis. Cell 2007;129:25-6.
22. Gao F, Shi HY, Daughty C, Cella N, Zhang M. Maspin plays an essential role in early embryonic development. Development 2004;131:1479-89.
23. Foster BA, Cunha GR. Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate. Endocrinology 1999;140:318-28.
24. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30.
25. Ford HL, Kabingu EN, Bump EA, Mutter GL, Pardee AB. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc Natl Acad Sci U S A 1998;95:12608-13.
26. Cunha GR, Hayward SW, Dahiya R, Foster BA. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel) 1996;155:63-72.
27. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
28. Roberts JM, Koff A, Polyak K, et al. Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol 1994;59:31-8.
29. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
30. Bill HM, Knudsen B, Moores SL, et al. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol 2004;24:8586-99.
31. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998;142:557-71.
32. Ding Q, Grammer JR, Nelson MA, Guan JL, Stewart JE, Jr., Gladson CL. p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain. J Biol Chem 2005;280:6802-15.
33. Bond M, Sala-Newby GB, Newby AC. Focal adhesion kinase (FAK)-dependent regulation of S-phase kinase-associated protein-2 (Skp-2) stability. A novel mechanism regulating smooth muscle cell proliferation. J Biol Chem 2004;279:37304-10.
34. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-6.
35. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-71.
36. Cella N, Contreras A, Latha K, Rosen JM, Zhang M. Maspin is physically associated with [β]1 integrin regulating cell adhesion in mammary epithelial cells. FASEB J 2006;20:1510-2.
37. Latha K, Zhang W, Cella N, Shi HY, Zhang M. Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol 2005;25:1737-48.
38. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 1993;4:897-906.
39. Gao H, Ouyang X, Banach-Petrosky W, et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2004;101:17204-9.
40. Sastry SK, Horwitz AF. Adhesion-growth factor interactions during differentiation: an integrated biological response. Dev Biol 1996;180:455-67.
41. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
42. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
43. Zhang F, Tom CC, Kugler MC, et al. Distinct ligand binding sites in integrin α3β1 regulate matrix adhesion and cell-cell contact. J Cell Biol 2003;163:177-88.
44. Robinson EE, Zazzali KM, Corbett SA, Foty RA. α5β1 integrin mediates strong tissue cohesion. J Cell Sci 2003;116:377-86.
45. Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70:506-21.
46. Gao N, Ishii K, Mirosevich J, et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005;132:3431-43.
47. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
48. Kasper S. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 2005;94:279-97.
49. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13:966-77.
50. Shen MM, Abate-Shen C. Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn 2003;228:767-78.